Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The FDA has a 60-day filing review period to determine whether the NDA is complete and accepted for review; Kura ...

Kura Oncology (KURA) announced Kura submitted a New Drug Application for ziftomenib, a highly selective, once-daily, oral, investigational ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...